Antibiotic-resistant infections kill tens of thousands of people and cost tens of billions of dollars each year, and though scientists are developing innovative methods to fight dangerous bacteria, market forces keep many investors on the sidelines. In response, the FDA and European Medicines Agency have offered expedited approval pathways and economic incentives, public-private financing mechanisms have emerged, and venture capitalists have set up targeted funds, but few drugmakers have stepped up development efforts.
Drugmakers hesitate to work on new antibiotics despite incentives
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.